The Netherlands is the first country to transition its national cervical cancer screening program from Pap to primary HPV screening
Listen to experts' perpectives:
A negative cobas® HPV Test provides more confidence that ≥CIN3 will not develop within 3 years vs cytology alone
The ATHENA study, the largest US prospective registrational clinical study of its kind, evaluated the performance of the HPV Primary Screening Algorithm with the cobas® HPV Test in women ages 25 and older. To review more of this data supporting a new paradigm in the fight against cervical cancer, click here.
Because cytology is known to have limited sensitivity1 and relies on subjective classifying borderline cytological abnormalities, it is possible that some women at risk of having or developing cervical pre-cancer may be overlooked for further testing and early intervention. Learn more here about why HPV Primary Screening is a better solution.
“The movement towards a national HPV screening program will lead to a more efficient and effective use of resources and, most importantly, fewer women will develop cervical cancer. Selecting the appropriate HPV test is a crucial first step for the success of this program.”
Dr. R.L.M. Bekkers
“We know that cytology has good, proven performance in reducing the burden of cervical cancers in the last 70 years ; however this has come to a crossroad. The new scientific evidence from multiple studies points to the greater value of HPV HR (high-risk) testing in primary screening – its sensitivity and negative predictive value - those are the most important parameters in a screening program.”
Dr. Teresa Fraga
1. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. J Clin Sci. 2006; 110:525-41.
Available at:http://www.clinsci.org/cs/110/0525/1100525.pdf. Accessed September 7, 2012.
*This module is designed to provide educational information about HPV and cervical cancer screening and prevention. While we do our best to fact check all information presented, you should not rely on this information as complete, or always up-to-date. The opinions provided in this video library are those of the speakers and may not be supported by Roche in their entirety.